Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to ...

A good night's sleep might be an additional benefit some gain from taking weight-loss drugs like Ozempic and Zepbound, a new ...

Biotech firm Apnimed plans to seek FDA approval for its sleep apnea drug, with market availability expected by 2027 ...

If you have obstructive sleep apnea (OSA)—a condition that causes a partial or complete collapse of your upper airway while sleeping—you’re likely familiar with continuous positive airway pressure ...

Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from trials in people with sleep apnea, the company ...

Congestion is one of the most common causes of snoring. A blocked nose can lead to mouth breathing, so clearing congestion ...

Around 22 million Americans have sleep apnea. Traditional continuous positive airway pressure, or CPAP, machines are the standard treatment. However, they can be loud, uncomfortable and have a pesky ...

Sleep apnea is a common sleep disorder that affects more than 20 percent of people in the United States. It happens when your breathing temporarily stops while you sleep. Depending on the severity of ...

Snoring is not a rare problem. In fact, according to the American Association of Oral and Maxillofacial Surgeons, right around half of Americans snore. Snoring can be frustrating and even though there ...

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine for obstructive sleep apnea, marking a major shift in the treatment of the ...

Research also suggests untreated sleep apnea is linked to a heightened risk of Parkinsons disease, a movement disorder ...